Core Insights - Cell and gene therapy (CGT) is recognized as a transformative biomedical technology aimed at treating diseases at their source, particularly in the ophthalmology sector, which is moving towards clinical application [1][2] - The industry is witnessing a strategic shift from focusing on rare genetic diseases to addressing common complex eye diseases, such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) [2][3] - The integration of capital into the CGT ecosystem is crucial for bridging the gap between laboratory breakthroughs and commercial implementation, with significant interest from investors [3][4] Industry Development - Advances in gene editing precision, standardization of stem cell therapies, and innovative delivery systems are propelling ophthalmic CGT from basic research to clinical application [2] - The market for ophthalmic CGT is expected to experience explosive growth due to increasing prevalence of eye diseases driven by aging populations and changing visual habits [2] Capital Empowerment - Capital is playing a pivotal role in connecting the innovation chain, industry chain, and funding chain, thereby accelerating the establishment of a comprehensive industrial ecosystem for ophthalmic CGT [3] - Over 40 CGT companies are reportedly queued for listing on the Hong Kong Stock Exchange in 2024, reflecting a 30% increase in valuation compared to the previous funding round, indicating strong market confidence in the sector [3] Company Strategies - He Eye Hospital Group is leveraging its comprehensive eye health ecosystem to focus on CGT, stem cell regenerative medicine, and smart ophthalmic equipment, aiming to integrate cutting-edge technology with healthcare data [4] - The company emphasizes an open ecosystem for CGT, fostering collaboration with other enterprises in technology and capital [4]
眼科CGT加速迈向临床转化阶段 资本赋能进一步给行业“加油”